Search This Blog

Friday, August 12, 2022

Do Traveling Health Workers Create More Problems Than They Solve?

 This discussion was recorded on July 21, 2022. This transcript has been edited for clarity.

Robert D. Glatter, MD: Welcome. I'm Dr Robert Glatter, medical advisor for Medscape Emergency Medicine. Today we have Dr Peter Papadakos, professor of anesthesiology and director of critical care medicine at University of Rochester Medical Center in New York, to discuss the ongoing staffing shortages affecting hospitals throughout the United States.

Welcome, Dr Papadakos.

Peter J. Papadakos, MD: Thank you very much for inviting me.

Glatter: Thank you so much for joining me. I wanted to talk about an interesting piece that you wrote in Anesthesiology News, titled "In the Care of Strangers: The Post-Pandemic Staffing Crisis." It really rang home to me because you visit many important points about the influx of locums providers, especially during COVID-19, and how it affected morale, team building, and cohesiveness among hospital staff. It was very eye-opening. Why are we in the midst of a national post–COVID-19 staffing crisis? What are the root causes of this?

Papadakos: As I point out in the article, it's a multiplicity of reasons. One is burnout. Many people worked incredibly long hours during COVID-19, including physicians, nurses, respiratory therapists, and all kinds of technicians. Then you had another component that added to this, which was the mandates for vaccinations, and some staff said, "I just don't want to deal with this." Then we had people who left the professions because of the pandemic, such as people with concomitant medical conditions who were afraid that suddenly working in a hospital was going to endanger their health, a spouse's health, or whatever.

We had a large drain of staffing at that point in time during the post-pandemic period. There's some pushback of young people entering healthcare fields because they saw that healthcare workers were on the front lines, endangering themselves initially, whereas a spouse or sibling who had an office job was working from home. As the demographic of people that enter healthcare changes, the level of dedication is not what it was 20, 30, or 40 years ago.

Glatter: How does this affect patient care directly? When you have many locums providers, temporary staffing agencies that are filling hospitals with people that are unfamiliar with certain protocols and take time to get up to speed, are there adverse effects on patient outcomes?

Papadakos: We have a multidisciplinary team made up of physicians, mid-level providers, nurses, and therapists. We've all practiced together and we work together on a daily basis as a team. It takes time to develop relationships.

Suddenly, with the influx of locums tenens and temporary people, you have people on 3- and 6-week contracts. They don't get oriented. They don't know who you are. You don't know what their capabilities are, what problems they might have, what skillsets are honed for them, and what skillsets they are deficient in. It completely decays that trust of the team that we use every day in the care of very sick patients in various environs of the hospital.

It's not only critical care areas but also the EDs and operating rooms that are affected by this team. We also have teams and groups that work on the floors taking care of less ill patients. Anecdotally, one of my colleagues told me they were running a code as an emergency medicine physician in a hospital in the Midwest. Suddenly the nurse goes, "Doctor, I'm not going to do that. We don't do that in California. That's not our first-line drug in California." That's not an appropriate conversation to be having during an acute event.

Glatter: I agree. Uniformity is an important point. When you bring in a temporary locums provider, do they go through training or simulation? Are there any protocols that hospitals have in place when they bring in people that are credentialed but maybe not familiar with the local flavor of how things run?

Papadakos: Initially, for nurses and our house staff, we're talking week-long orientations over extended periods of time that were normally happening prior to the pandemic. When you have somebody on a 5-week contract, you're not going to be able to do an orientation program for them. You're using that person immediately because you're filling a hole in your schedule or a hole to keep your beds open because many states require nurse-to-patient ratios. If you don't have enough staff, you're going to be browning out beds, which is going to be a major problem.

It's not only hospitals. It's also nursing homes that are going through this. They don't have enough certified nurse assistants and nurses so they're not able to take admissions. Then you get another backlog at the hospital.

This whole shift from permanent employment at a hospital, nursing home, doctor office, or satellite clinic has massively impacted the patient flow.

Glatter: What can we do to reduce attrition and migration to staffing agencies that current employees are seeing, and new graduates? Offer salary increases, bonuses, paid time off, wellness, and so on?

Papadakos: What I think we need to do as clinicians is start working with the people in our C-suites (ie, the leadership of the hospital) because we and they cannot survive this as a long-term staffing issue. In healthcare, you need to have teams. You need to have people who are experienced working together on a regular basis, so we need to try to mitigate that attrition.

One of the problems that we have is when we bring in locums in any hospital, their salary is many multiples over your current bedside staff, which makes the bedside staff develop a certain hatred.

One of the things that we can't control as clinicians is how to start elevating the salary of our allied health providers, including nurses, respiratory therapists, technologists, and x-ray techs, so that they're less likely to leave the institution.

If you talk to any locums or anybody else, what you make as a salary is a very important thing. We're very material people. Obviously, working conditions, being more open for scheduling. One of the things I've been told by colleagues is the ability to provide daycare onsite for health providers who have young children. Professional education benefits (ie, CME for physicians, nursing credits), helping with tuition for a nurse to get a more advanced degree to become a nurse practitioner, or a therapist to move up the academic ranks. These are all things that we can do. Again, what is the mechanism with the limited funds of hospitals to be able to do those things?

Glatter: The reality is that locum staffing is not going to go away. We both know that. It does fill a need when someone has an accident, an injury, or is sick and we need someone immediately. There is a role for it, but sustainability is the question here, and in terms of the solvency of hospitals, is really at risk. I think you pointed that out in your article.

Papadakos: You hit the nail on the head. The solvency of the hospitals has definitely decayed. The bottom line is decay. The hospitals are bleeding money because they are paying many more multiples of salaries that they never expected, based on fixed reimbursement from Medicare and Medicaid. Your private insurance companies did not increase reimbursement because you are now staffing 50% of your staff as locum tenants. The hospital will eventually become insolvent, or before they become insolvent, hospitals will start cutting down services, be it freestanding emergency rooms, obstetrics and gynecology services, outpatient clinics, and so on.

Hospitals throughout the country, as it's been pointed out in the literature, are closing down services in a time where we need more services.

Glatter: Absolutely, and this is a problem. The rural areas especially are going to be the hardest hit with closures, but also urban areas are not immune. The federal government may have to play a role here to rescue some of these institutions because of the staffing crisis and the economics of it.

Papadakos: You bring up an important point, but I have not seen any of our legislators, be it at the state or the national level, that are even aware that this is happening, and the whole American health system is becoming insolvent. I would think, as I pointed out in my article, that this would be breaking news that most hospitals are now staffed by nontraditional means. They're all in financial distress. Services are being cut down. I've not seen anything or heard much on the national or local media reporting on this.

Glatter: Absolutely. The effect of climate change on the practice of medicine is another thing we can't ignore.

Papadakos: We're also going to see seasonal variation. It's not only the heat wave. Many nurses from northern states who don't like driving through snowstorms are going to leave the area to go down South and take contracts in the Sun Belt. Nurses who normally would come up from the Sun Belt to the northern environments are not exactly going to want to work in Buffalo in January.

The other thing that's happening, which is kind of interesting, is when you talk to physicians and other health providers in large cities, what we have are "musical chairs" locums. You have major university hospitals that have nurses from the other major university hospital down the street. It's just like rotating chairs. Nurses from hospital A are working in hospital B, nurses in D are working in E, and they keep rotating vs having a set staff. They don't even have to leave their area.

Big cities might have an advantage with what I call local locums people vs small, rural, acute care hospitals. They're not going to get staff that's in the area and have been working at a competing institution. They're going to close beds and may have to close down. Closing down a rural, acute need hospital is catastrophic for the people in the area.

Glatter: I think this should be front and center in the news cycle. I think that the public really needs to have an awareness of this, and it must be brought to a legislative level — if not at the hospital level, then at the state level — to really look at this critical staffing shortage that exists.

Papadakos: Another thing is happening that makes no sense to me. Yes, you can make more money traveling, but suddenly you also have no insurance and no 401(k). There are many other benefits that people get. You now have possibly many healthcare professionals who are uninsured.

The temptation is you get lots of money, but you're used to somebody else paying your premiums (ie, your employer). Your employer used to give you a 401(k), educational benefits, or whatever. You're not getting any of those things. We're creating people who have temporary financial gain but may not have long-term stability.

Glatter: The locums companies will give you data saying that the typical profile of a provider is someone who is 20-25 years in practice, older into their fifties or sixties, and at the end of their career. A very small percentage are younger. I believe it was 10%, according to one report. This age differential and experience gap is what they will show you in terms of their data. The kind of providers that we're seeing, or at least on my end, are younger rather than the older provider. Maybe you could explain this disconnect.

Papadakos: You're right. The model 10-15 years ago was the retiree who would want to see the country and get put up in a garden apartment in Arizona with a pool. There was a limited number of locums people. The locums company telling me about something that existed 5-10 years ago is not the truth that you will have now. If you look around any hospital, you'll see that the majority of your locums nurses or anesthesia providers are young people who are 1-2 years out of training. We're talking about people in their twenties and thirties. We're not talking about the data that they're showing, with retirees and people at the end of their career. That is what they used to do.

Also, if you talked to a locums company previously, they may have had 20 or 30 people on contract. The locums companies now have tens of thousands of people on contracts. I was not being actively recruited to join a locums company 20 or 30 years ago. It was something you heard about from an older physician through word of mouth. Now it's out there and everybody knows about it.

When you bring locums into a hospital — especially as nursing, mid-level, advanced practitioner, respiratory therapy, x-ray tech, lab technologists, anesthesia techs, operating room scrub technologists — the technologist who is working at your institution finds out about the cash rewards of joining the locums company, and they will want to join the locums company.

Glatter: The reality is that many young doctors are in debt and they see the financial rewards of locums as a way to pay back their debt. That might be a motivation that lures them in.

Papadakos: One of the other things is that we need a new type of hospital management because none of them have ever dealt with this problem before. Every C-suite, chair, and nursing director is in shock because this has never happened before. I've heard of CEOs of hospitals planning early retirement so that they're not at the helm of a health system when it goes bankrupt.

Glatter: Absolutely. Patient outcomes will be the important part of this crisis that we're facing. Are we going to see increased numbers of patients with poor outcomes or longer lengths of stay? It's going to translate into adverse effects.

Papadakos: We already have some reports. Hospital-acquired infections have gone up because people are not familiar with the guidelines and protocols of a specific institution that they're now working in. Regarding the reporting system for quality, a locums doesn't know how to report an issue in the quality-assurance system of whatever institution they are in. It takes time and practice to develop that. We're going to see massive increases in outcome problems and a decay in a robust quality-assurance patient safety system that's been developed over the last number of decades. There's no buy-in if you're there as a temporary.

Glatter: Right. There's no federal reporting system in the era of locums, especially since COVID-19, that I'm aware of, that integrates these outcomes or patient safety issues with these providers that come into hospitals at a moment's notice. That's an important thing that we need to address.

Papadakos: What is going to happen to the medical-legal system, the malpractice system? What is the coverage and responsibility of the locums company for providing a subpar individual who suddenly caused a bad outcome? What is the legal responsibility of the employer, the hospital, that suddenly has somebody who isn't fully vetted in their own system and does something (ie, there's a bad outcome)? It's a multilevel problem that needs to be addressed.

Glatter: These are important issues that we've discussed and hopefully these can be addressed. Thank you for your time, your expertise, and your insight on this issue.

Robert D. Glatter, MD, is assistant professor of emergency medicine at Lenox Hill Hospital in New York City and at Zucker School of Medicine at Hofstra/Northwell in Hempstead, New York. He is an editorial advisor and hosts the Hot Topics in EM series on Medscape. He is also a medical contributor for Forbes.

Peter J. Papadakos, MD, is professor of anesthesiology and director of critical care medicine at University of Rochester Medical Center in New York, a position he has held since 2000. His research focuses on pulmonary critical care management, including work on septic shock and oxygen delivery, the pathophysiology of acute lung failure, and the use of nitric oxide in acute respiratory distress syndrome. He is extensively published in professional journals and has been featured as a guest expert for various media outlets, including The New York Times and The Washington Post.

https://www.medscape.com/viewarticle/977617

U.S. monkeypox cases surpass 10,000 as CDC still aims for 'containment'

 More than 10,000 Americans have now tested positive in the monkeypox outbreak across the U.S., according to figures published late Wednesday by the Centers for Disease Control and Prevention, as federal health officials say they are still racing to contain the virus.

Cases have been reported in every state but Wyoming while 15 states and the District of Columbia have reported more than a hundred cases. The largest numbers are in New York, California and Florida.

No U.S. deaths have so far been reported, out of the 12 monkeypox fatalities the World Health Organization has tallied so far this year.

Health officials say the virus is mostly spreading through close interactions between men who have sex with men, either through direct skin-to-skin contact or shared linens like towels and bedding. 

However, the CDC has tallied at least 50 cases in people who were female at birth, including at least one pregnant woman. A handful of suspected infections have also been spotted in young children, although health authorities recently said some may have actually been false positives. 

Federal health authorities have warned for weeks that they expected the U.S. outbreak to accelerate through August, especially as availability of testing ramped up, following the course of some other European countries that saw cases swell earlier in the year. 

The U.S. has reported the most infections of any country in the world since late July. The American sum of cases is now roughly double the size of Spain, the European nation that had previously reported the most cases ahead of Germany and the United Kingdom.

The pace of new cases now appears to be slowing in some countries abroad. When measured relative to the size of each nation's population, the CDC's tally is still smaller than in those European nations, though the accelerating U.S. outbreak now appears on pace to eclipse those rates too. 

For states with more than 25 cases, CDC officials recently estimated that the pace of new monkeypox infections is doubling every 8.6 days on average. 

On Wednesday, 1,391 new cases were reported nationwide to the CDC — the largest single-day increase so far. The first known case in the current U.S. outbreak was reported in mid-May.

"We are still operating under a containment goal, although I know many states are starting to wonder if we're shifting to more of a mitigation phase right now, given that our case counts are still rising rapidly," Jennifer McQuiston, the CDC's top monkeypox official, told a group of the agency's outside advisers on Tuesday.

That effort might get easier over the coming weeks, following a move by the Food and Drug Administration this week to grant emergency use authorization to a method of using smaller doses of the Jynneos monkeypox vaccine that could effectively multiply the U.S. supply of the shots

By administering these smaller doses between the skin's layers, instead of deeper into the arm, authorities say it may be possible to vaccinate up to five times as many people with each vial and still yield a "nearly identical" immune response.

However, the CDC has long warned there was limited data showing how effective the Jynneos vaccine is at actually curbing monkeypox disease and transmission — urging those vaccinated to continue taking "steps to protect themselves from infection" during the outbreak. 

The agency has previously reported on a handful of reports of reported breakthrough infections following at least one shot of the two-dose Jynneos vaccine. Early data from France, where the vaccine is branded as Imvanex, also tallied breakthrough infections.

Local health officials caution it will take time for them to ramp up the new "intradermal" approach to vaccinations, which relies on different needles and procedures than the traditional "subcutaneous" shot. 

"We won't just sort of say 'start.' We will make sure people will have updated provider agreements, updated training requirements, all of this. And you know, our first call with the CDC about this is on Friday, just to give you a sense that this is a process. It's not, 'here's the EUA, go'," Dr. Allison Arwady, Chicago's top health official. 

Arwady, who is the vice chair of the Big Cities Health Coalition, estimated that around the country it could take up to three weeks for local health departments to begin the new dose-sparing approach.

Citing limited supply, the CDC currently says it does not encourage "mass vaccination for the general public or for all sexually active people." Instead, the agency says shots should be prioritized first for people with HIV, pregnant and very young people, and others who are considered at high risk for severe disease

But with supply now growing in the wake of the FDA's move, McQuiston said the CDC might soon move to expand eligibility for the shots to broader groups of people. 

Officials are also weighing use of the older ACAM2000 vaccine, despite concerns that it carries some more side effects and risks than Jynneos. 

"There are millions of doses of ACAM2000 in the system. And some of our modeling here at CDC suggests that it could play an important role in bringing this outbreak to a close, if it was used carefully," said McQuiston. 

https://www.cbsnews.com/news/monkeypox-cases-10000-cdc-containment-vaccine/

Mistrial declared over engineers' role in Flint water crisis

 A judge declared a mistrial Thursday after jurors said they couldn’t reach a unanimous verdict in a dispute over whether two engineering firms should bear some responsibility for Flint’s lead-contaminated water.

Veolia North America and Lockwood, Andrews & Newman, known as LAN, were accused of not doing enough to get Flint to treat the highly corrosive water or to urge a return to a regional water supplier.

The eight-person jury met for roughly seven days after hearing evidence for months. The jury first signaled on July 28 that it couldn’t reach a verdict before taking a planned 11-day break. The group returned to work Tuesday.

“Further deliberations will only result in stress and anxiety with no unanimous decision without someone having to surrender their honest convictions, solely for the purpose of returning a verdict,” the jury said in a new note Thursday.

U.S. Magistrate Judge David Grand declared a mistrial, rejecting a request by lawyers for four children to allow a verdict that’s less than unanimous.

“This is not a focus group,” Grand said.

The trial centered on the engineering firms and the effects of lead on the children, not all Flint residents. But the result was being closely watched because there are other cases pending against Veolia and LAN.

The firms were not part of a landmark $626 million deal involving property owners, thousands of residents of the majority-Black city, the state of Michigan and other parties.

“We don’t see this as a defeat,” Veolia attorney Dan Stein told The Associated Press. “The plaintiffs were the ones trying to prove their claims to the jury, and they were unable to do so.”

Corey Stern, an attorney for the children, said he was only one juror shy from winning the case. The lack of a verdict means a trial can be held again with a different jury.

“I’m fired up for the next one,” Stern said. “I wish the judge would schedule it for Monday. I hated leaving the courthouse. You’re an inch from the goal line after toting the ball for 99 yards.”

Flint’s water became contaminated in 2014-15 because water pulled from the Flint River wasn’t treated to reduce the corrosive effect on lead pipes. Citing cost, managers appointed by then-Gov. Rick Snyder stopped using water from a Detroit agency and switched to the river while awaiting a new pipeline to Lake Huron.

The Michigan Civil Rights Commission said the bad water was the result of systemic racism in the city, doubting that the water switch and the spurning of complaints would have occurred in a white, prosperous community.

During closing arguments, attorneys for the children argued that Veolia should be held 50% responsible for lead contamination and that LAN should be held 25% responsible, with public officials making up the balance.

But Veolia’s lawyers noted the firm was briefly hired in the middle of the crisis, not before the spigot was turned on. LAN said an engineer repeatedly recommended that Flint test the river water for weeks to determine what treatments would be necessary.

LAN attorney Wayne Mason said outside engineers were getting lumped in with a “platoon of bad actors,” namely state and local officials who controlled all major decisions about the water. The health effects on the four children were also challenged at trial.

Snyder was summoned as a witness but declined to answer questions, citing his right against self-incrimination.

He was indicted on misdemeanor charges in a separate Flint water investigation. The Michigan Supreme Court said the indictment was invalid, though state prosecutors are trying to reinstate the charges.

The jury instead watched a video of Snyder’s 2020 interview with lawyers.

“I wish this never would have happened,” he said of the water mess, acknowledging mistakes by government.

https://www.nbcnews.com/news/us-news/mistrial-declared-jury-cant-reach-verdict-engineers-flint-water-trial-rcna42770

'Disturbing' Canada euthanasia laws due to expand

 Alan Nichols had a history of depression and other medical issues, but none were life-threatening. When the 61-year-old Canadian was hospitalized in June 2019 over fears he might be suicidal, he asked his brother to “bust him out” as soon as possible.

Within a month, Nichols submitted a request to be euthanized and he was killed, despite concerns raised by his family and a nurse practitioner.

His application for euthanasia listed only one health condition as the reason for his request to die: hearing loss.

Nichols’ family reported the case to police and health authorities, arguing that he lacked the capacity to understand the process and was not suffering unbearably — among the requirements for euthanasia. They say he was not taking needed medication, wasn’t using the cochlear implant that helped him hear, and that hospital staffers improperly helped him request euthanasia.

“Alan was basically put to death,” his brother Gary Nichols said.

Disability experts say the story is not unique in Canada, which arguably has the world’s most permissive euthanasia rules — allowing people with serious disabilities to choose to be killed in the absence of any other medical issue.

Many Canadians support euthanasia and the advocacy group Dying With Dignity says the procedure is “driven by compassion, an end to suffering and discrimination and desire for personal autonomy.” But human rights advocates say the country’s regulations lack necessary safeguards, devalue the lives of disabled people and are prompting doctors and health workers to suggest the procedure to those who might not otherwise consider it.

Equally troubling, advocates say, are instances in which people have sought to be killed because they weren’t getting adequate government support to live.

Canada is set to expand euthanasia access next year, but these advocates say the system warrants further scrutiny now.

Euthanasia “cannot be a default for Canada’s failure to fulfill its human rights obligations,” said Marie-Claude Landry, the head of its Human Rights Commission.

Landry said she shares the “grave concern” voiced last year by three U.N. human rights experts, who wrote that Canada’s euthanasia law appeared to violate the agency’s Universal Declaration of Human Rights. They said the law had a “discriminatory impact” on disabled people and was inconsistent with Canada’s obligations to uphold international human rights standards.

Tim Stainton, director of the Canadian Institute for Inclusion and Citizenship at the University of British Columbia, described Canada’s law as “probably the biggest existential threat to disabled people since the Nazis’ program in Germany in the 1930s.”

During his recent trip to Canada, Pope Francis blasted what he has labeled the culture of waste that considers elderly and disabled people disposable. “We need to learn how to listen to the pain” of the poor and most marginalized, Francis said, lamenting the “patients who, in place of affection, are administered death.”

Canada prides itself on being liberal and accepting, said David Jones, director of the Anscombe Bioethics Centre in Britain, “but what’s happening with euthanasia suggests there may be a darker side.”

___

Euthanasia, where doctors use drugs to kill patients, is legal in seven countries — Belgium, Canada, Colombia, Luxembourg, Netherlands, New Zealand and Spain — plus several states in Australia.

Other jurisdictions, including several U.S. states, permit assisted suicide — in which patients take the lethal drug themselves, typically in a drink prescribed by a doctor.

In Canada, the two options are referred to as medical assistance in dying, though more than 99.9% of such deaths are euthanasia. There were more than 10,000 deaths by euthanasia last year, an increase of about a third from the previous year.

Canada’s road to allowing euthanasia began in 2015, when its highest court declared that outlawing assisted suicide deprived people of their dignity and autonomy. It gave national leaders a year to draft legislation.

The resulting 2016 law legalized both euthanasia and assisted suicide for people aged 18 and over provided they met certain conditions: They had to have a serious condition, disease or disability that was in an advanced, irreversible state of decline and enduring “unbearable physical or mental suffering that cannot be relieved under conditions that patients consider acceptable.” Their death also had to be “reasonably foreseeable,” and the request for euthanasia had to be approved by at least two physicians.

The law was later amended to allow people who are not terminally ill to choose death, significantly broadening the number of eligible people. Critics say that change removed a key safeguard aimed at protecting people with potentially years or decades of life left.

Today, any adult with a serious illness, disease or disability can seek help in dying.

Canadian health minister Jean-Yves Duclos said the country’s euthanasia law “recognizes the rights of all persons ... as well as the inherent and equal value of every life.”

The countries that allow euthanasia and assisted suicide vary in how they administer and regulate the practices, but Canada has several policies that set it apart from others. For example:

— Unlike Belgium and the Netherlands, where euthanasia has been legal for two decades, Canada doesn’t have monthly commissions to review potentially troubling cases, although it does publish yearly reports of euthanasia trends.

— Canada is the only country that allows nurse practitioners, not just doctors, to end patients’ lives. Medical authorities in its two largest provinces, Ontario and Quebec, explicitly instruct doctors not to indicate on death certificates if people died from euthanasia.

— Belgian doctors are advised to avoid mentioning euthanasia to patients since it could be misinterpreted as medical advice. The Australian state of Victoria forbids doctors from raising euthanasia with patients. There are no such restrictions in Canada. The association of Canadian health professionals who provide euthanasia tells physicians and nurses to inform patients if they might qualify to be killed, as one of their possible “clinical care options.”

— Canadian patients are not required to have exhausted all treatment alternatives before seeking euthanasia, as is the case in Belgium and the Netherlands.

Still, Duclos said there were adequate safeguards in place, including “stringent eligibility criteria” to ensure no disabled people were being encouraged or coerced into ending their lives. Government figures show more than 65% of people are being euthanized due to cancer, followed by heart problems, respiratory issues and neurological conditions.

Theresia Degener, a professor of law and disability studies at the Protestant University for Applied Sciences in northwestern Germany, said allowing euthanasia based exclusively on disability was a clear human rights violation.

“The implication of (Canada’s) law is that a life with disability is automatically less worth living and that in some cases, death is preferable,” said Degener.

___

Alan Nichols lost his hearing after brain surgery at age 12 and suffered a stroke in recent years, but he lived mostly on his own. “He needed some help from us, but he was not so disabled that he qualified for euthanasia,” said Gary Nichols.

In one of the assessments filed by a nurse practitioner before Nichols was killed, she noted his history of seizures, frailty and “a failure to thrive.” She also wrote that Nichols had hearing and vision loss.

The Nichols family were horrified that his death appeared to be approved based partly on Alan’s hearing loss and had other concerns about how Alan was euthanized. They lodged complaints with the British Columbia agency that regulates doctors and the Royal Canadian Mounted Police, asking for criminal charges. They also wrote to Canada’s minister of justice.

“Somebody needs to take responsibility so that it never happens to another family,” said Trish Nichols, Gary’s wife. “I am terrified of my husband or another relative being put in the hospital and somehow getting these (euthanasia) forms in their hand.”

The hospital says Alan Nichols made a valid request for euthanasia and that, in line with patient privacy, it was not obligated to inform relatives or include them in treatment discussions.

The provincial regulatory agency, British Columbia’s College of Doctors and Surgeons, told the family it could not proceed without a police investigation. In March, Royal Canadian Mounted Police Cpl. Patrick Maisonneuve emailed the relatives to say he had reviewed the documentation and concluded Alan Nichols “met the criteria” for euthanasia.

The family’s parliamentary representative, Laurie Throness, asked British Columbia’s health minister for a public investigation, calling the death “deeply disturbing.”

The health minister, Adrian Dix, said the province’s oversight unit reviewed the case and “has not referred it for any further inquiry.” He pointed out that the euthanasia law does not allow for families to review euthanasia requests or be privy to hospitals’ decisions.

Trudo Lemmens, chair of health law and policy at the University of Toronto, said it was “astonishing” that authorities concluded Nichols’ death was justified.

“This case demonstrates that the rules are too loose and that even when people die who shouldn’t have died, there is almost no way to hold the doctors and hospitals responsible,” he said.

___

Some disabled Canadians have decided to be killed in the face of mounting bills.

Before being euthanized in August 2019 at age 41, Sean Tagert struggled to get the 24-hour-a-day care he needed. The government provided Tagert, who had Lou Gehrig’s disease, with 16 hours of daily care at his home in Powell River, British Columbia. He spent about 264 Canadian dollars ($206) a day to pay coverage during the other eight hours.

Health authorities proposed that Tagert move to an institution, but he refused, saying he would be too far from his young son. He called the suggestion “a death sentence” in an interview with the Canadian Broadcasting Corporation.

Before his death, Tagert had raised more than CA$16,000 ($12,400) to buy specialized medical equipment he needed to live at home with caretakers. But it still wasn’t enough.

“I know I’m asking for change,” Tagert wrote in a Facebook post before his death. “I just didn’t realize that was an unacceptable thing to do.”

Stainton, the University of British Columbia professor, pointed out that no province or territory provides a disability benefit income above the poverty line. In some regions, he said, it is as low as CA$850 ($662) a month — less than half the amount the government provided to people unable to work during the COVID-19 pandemic.

Heidi Janz, an assistant adjunct professor in Disability Ethics at the University of Alberta, said “a person with disabilities in Canada has to jump through so many hoops to get support that it can often be enough to tip the scales” and lead them to euthanasia.

Duclos, the national health minister, told The Associated Press that he could not comment on specific cases but said all jurisdictions have a broad range of policies to support disabled people. He acknowledged “disparities in access to services and supports across the country.”

Other disabled people say the easy availability of euthanasia has led to unsettling and sometimes frightening discussions.

Roger Foley, who has a degenerative brain disorder and is hospitalized in London, Ontario, was so alarmed by staffers mentioning euthanasia that he began secretly recording some of their conversations.

In one recording obtained by the AP, the hospital’s director of ethics told Foley that for him to remain in the hospital, it would cost “north of $1,500 a day.” Foley replied that mentioning fees felt like coercion and asked what plan there was for his long-term care.

“Roger, this is not my show,” the ethicist responded. “My piece of this was to talk to you, (to see) if you had an interest in assisted dying.”

Foley said he had never previously mentioned euthanasia. The hospital says there is no prohibition on staff raising the issue.

Catherine Frazee, a professor emerita at Toronto’s Ryerson University, said cases like Foley’s were likely just the tip of the iceberg.

“It’s difficult to quantify it, because there is no easy way to track these cases, but I and other advocates are hearing regularly from disabled people every week who are considering (euthanasia),” she said.

Frazee cited the case of Candice Lewis, a 25-year-old woman who has cerebral palsy and spina bifida. Lewis’ mother, Sheila Elson, took her to an emergency room in Newfoundland five years ago. During her hospital stay, a doctor said Lewis was a candidate for euthanasia and that if her mother chose not to pursue it, that would be “selfish,” Elson told the Canadian Broadcasting Corporation.

___

Canada has tweaked its euthanasia rules since they were first enacted six years ago, but critics say more needs to be done — especially as Canada expands access further.

Next year, the country is set to allow people to be killed exclusively for mental health reasons. It is also considering extending euthanasia to “mature” minors — children under 18 who meet the same requirements as adults.

Chantalle Aubertin, spokeswoman for Canadian Justice Minister David Lametti, said in an email that the government had taken into account concerns raised by the disabled community when it added safeguards to its euthanasia regulations last year. Those changes included that people were to be informed of all services, such as mental health support and palliative care, before asking to die.

Aubertin said those and other measures would “help to honor the difficult and personal decisions of some Canadians to end their suffering on their own terms, while enshrining important safeguards to protect the vulnerable.”

Dr. Jean Marmoreo, a family physician who regularly provides euthanasia services in Ontario, has called for specialized panels to provide a second opinion in difficult cases.

“I think this is not something you want to rush, but at the same time, if the person has made a considered request for this and they meet the eligibility criteria, then they should not be denied their right to a dignified death,” she said.

Landry, Canada’s human rights commissioner, said leaders should listen to the concerns of those facing hardships who believe euthanasia is their only option. She called for social and economic rights to be enshrined in Canadian law to ensure people can get adequate housing, health care and support.

“In an era where we recognize the right to die with dignity, we must do more to guarantee the right to live with dignity,” she said.

https://apnews.com/article/covid-science-health-toronto-7c631558a457188d2bd2b5cfd360a867

AMA aims to increase screenings for HIV, STIs, hepatitis, tuberculosis

 With declines in clinical visits for HIV, sexually transmitted infections (STIs), and other evidence-based preventive services in the U.S. during the COVID-19 pandemic, the American Medical Association (AMA) today announced a new initiative aimed at helping physicians and other health care professionals increase routine screenings for HIV, STIs, viral hepatitis and latent tuberculosis (LTBI).

As part of this effort, the AMA, with the support of the Centers for Disease Control and Prevention (CDC), worked to understand key barriers and drivers for implementing routine screening and developed a toolkit to provide best practices and strategies to enhance screening programs. The AMA is collaborating with the following community health center sites that will test the quality improvement strategies outlined in the toolkit to determine their impact on routine screening, as well as provide overall feedback on the toolkit before it is disseminated more broadly:

  • CCI Health Services, Silver Spring, MD
  • Circle the City, Phoenix, AZ
  • Esperanza Health Centers, Chicago, IL
  • Jackson-Hinds Comprehensive Health Center, Jackson, MS
  • Odyssey House Louisiana, New Orleans, LA
  • Outreach Health Services, Inc, Shubuta, MS

"Routine screening and early detection of HIV, STIs, viral hepatitis, and LTBI are critical to ensure patients receive treatment and also lower their risk of transmitting these infectious diseases to others," said AMA President Jack Resneck Jr., M.D. "Given that access to preventive services were interrupted by the COVID-19 pandemic, many individuals may not even be aware they have an infection and are at risk of contributing to new infections. We know that social inequities and stigma continue to be barriers to screening. We believe this new toolkit will help increase screenings and prevent further spread of these infectious diseases. Additionally, with the monkeypox virus outbreak declared a public health emergency, the overlap in populations disproportionally affected, and the benefits of a syndemic approach, we look forward to the opportunity to work with the clinic sites in addressing this public health threat.”

“Getting diagnosed before an infection causes serious illness should be the norm—not the exception,” said Jonathan Mermin, M.D., M.P.H., Director of CDC’s National Center for HIV, Viral Hepatitis, STD, and TB Prevention. “Routine screening saves lives, increases health equity, and reduces health care costs. This AMA-CDC collaboration supports evidence-based strategies to effectively and efficiently scale up routine screening.”

The AMA has extensive policy supporting evidence-based preventive services, including screening for these infectious diseases. We recognize that routine universal screening helps protect not only individual patients, but the health of the public. The AMA is a Dissemination and Implementation partner of the U.S. Preventive Services Task Force and also supports the U.S. Department of Health and Human Services initiative focused on Ending the HIV Epidemic in the U.S.

This effort is supported by the CDC of the U.S. Department of Health and Human Services (HHS) as part of CDC-RFA-OT18-1802: Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health with award totaling $999,696 with 100% funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.

https://www.ama-assn.org/press-center/press-releases/ama-aims-increase-screenings-hiv-stis-hepatitis-tuberculosis

COVID rebound is surprisingly common — even without Paxlovid

 After the game-changing COVID-19 antiviral Paxlovid began to be used in late 2021, researchers noticed a perplexing trend. In some people taking the drug, symptoms and detectable virus vanish, only to mysteriously return days later.

After months of grasping at straws, scientists are beginning to make some headway in understanding ‘Paxlovid rebound’. Two recent studies suggest that it is surprisingly common for SARS-CoV-2 to return in untreated cases of COVID-191, while hinting that the virus’s comeback is fiercer and more common in people who take Paxlovid2.

“We’re all seeing people who are taking Paxlovid doing really well and then suddenly they’re getting sick again,” says Michael Charness, a physician-scientist at VA Boston Healthcare in Massachusetts, who published an early description of Paxlovid rebound3. “There are so many unanswered questions.”

Viral resurgence

Paxlovid ― a combination of the oral antiviral drugs nirmatrelvir and ritonavir ― has been a boon in countries where it is widely available. A clinical trial sponsored by the manufacturer Pfizer, headquartered in New York City, showed that it reduced the risk of hospitalization and death in at-risk unvaccinated individuals4. Real-world studies suggest the therapy’s benefits could also extend to vaccinated people5.

The Pfizer trial team noticed cases of rebound both in people who got Paxlovid and in those who took a placebo4. But complete details of these cases are not available, scientists say.

To determine the frequency of rebound in the absence of Paxlovid treatment, Jonathan Li, a physician-scientist at Brigham and Women’s Hospital in Boston, Massachusetts, and his team analysed data from hundreds of people who were randomized to receive a placebo in a large-scale trial of COVID-19 antibody drugs.

More than one-quarter of participants who were infected with SARS-CoV-2 reported a rebound in their symptoms, while 1 in 8 saw the virus return to high levels1. Yet, just 1–2% of people had both features of rebound. The study was posted to the medRxiv preprint server on 2 August and has not yet been peer reviewed.

Covid comeback: People who receive the antiviral Paxlovid can experience a rebound in symptoms and viral levels.

Source: Ref 1.

Li says that this suggests that the rebound of SARS-CoV-2 rarely causes symptoms, and that symptoms’ reappearance could stem instead from factors other than viral resurgence, such as lingering immune responses or another infection altogether. “The main take-home message is that recovery from COVID-19 is not going to be a linear process”, Li says.

Li’s team, as well as many others, are now studying people who take Paxlovid both before and after rebound tends to occur. One such study found signs that Paxlovid rebound is different to the resurgences that occur without treatment2. The study, posted to medRxiv on 4 August, has not yet been peer reviewed.

The study, led by infectious-disease physician and vaccine scientist Kathryn Stephenson at Beth Israel Deaconess Medical Center in Boston, closely followed 11 people who took Paxlovid for COVID-19 and 25 who did not. More than one-quarter of the Paxlovid recipients rebounded, based on levels of SARS-CoV-2, compared with just one of the 25 untreated people. Moreover, people with Paxlovid rebound had high levels of virus for several days, as if they had new acute infections. “The single case of viral rebound without treatment was more like a viral ‘blip’,” Stephenson wrote on Twitter.

Charness says that Paxlovid rebound does seem to be qualitatively different from rebound in untreated people, whose viral levels rarely reached the peaks of their initial infection.

But the cause of Paxlovid rebound remains unclear. Studies have suggested that it’s unlikely to be due to viral drug resistance or feeble immune responses in rebounders. Researchers are testing whether viral replication, having been suppressed by Paxlovid, can bounce back when the drug vanishes from the body, leading to high viral levels and potent immune responses that can cause symptoms to reappear.

Physicians also need a better guide as to how to treat, and ultimately prevent, Paxlovid rebound. Mark Siedner, a clinical epidemiologist at Massachusetts General Hospital in Boston who is studying Paxlovid rebound, says the phenomenon reminds him of what occurs when other diseases are treated for too short a time. “This smells like treatment duration is not long enough for the subgroup of people who have rebound.”

The drug is currently given for five days, but Charness says it’s worth looking at longer treatment periods — as long as this doesn’t promote drug resistance. “There is still a lot to learn.”

doi: https://doi.org/10.1038/d41586-022-02121-z

https://www.nature.com/articles/d41586-022-02121-z

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

 Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld.

That’s the position of multiple patient organisations, clinicians and medical groups, who have criticised the Department of Health’s decision to defer procurement of Evusheld supplies until cost-effectiveness agency NICE has evaluated whether the antibody has durable efficacy against the prevailing Omicron variant of SARS-CoV-2.

AZ has conformed that it has not been asked to keep any Evusheld stock aside for the UK this coming winter, said lobby group Evusheld for the UK in a statement (PDF).

The drug – based on antibodies tixagevimab and cilgavimab – was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in March, becoming the first alternative to vaccines for pre-exposure prophylaxis of COVID-19.

The NICE appraisal isn’t expected until next April, leaving immunocompromised patients with little choice but to continue to protect themselves with isolation several more months at least.

Upwards of 18 charities including Blood Cancer UK, the MS Society, the Anthony Nolan Trust and Action for Pulmonary Fibrosis have written a letter to Health Secretary Steve Barclay that argues there is strong clinical support for Evusheld, which is being held to an “impossible standard of evolving evidence.”

The Department of Health and Social Care says that it has conducted a “robust review” of Evusheld, and concluded that there is “currently insufficient data on the duration of protection offered” by the drug “in relation to the Omicron variant.”

The charities are asking the government to publish its evidence for the decision, noting it is at odds with the conclusions of dozens of other countries which have made the drug available to vulnerable people.

They also say that similar demands have not been of any other COVID therapeutic, and failure the provide the drug could increase pressure on NHS beds over the winter.

“The reality is that there is excellent real-world phase 4 data from other countries, such as Israel and France, showing massively reduced hospitalisations and mortality rates,” claims Evusheld for the UK

“Our members are also less interested in the long-term, durational protection. Our members would simply like to have their first family Christmas in three years, while the protection lasts.”

AZ reported lab data in May, generated by scientists at the University of Oxford, which showed that Evusheld retained neutralising activity against Omicron variants BA.4 and BA.5, currently dominant in the UK.

One group of Chinese researchers has reported however that BA.4 and BA.5 subvariants with R346 mutations on the spike glycoprotein completely escaped neutralisation with the antibody combination, while Eli Lilly’s bebtelovimab retained activity.

https://pharmaphorum.com/news/dismay-as-uk-drags-its-heels-on-azs-covid-antibody-evusheld/